Back to Market Feed

DALIRESP 250 MCG TABLET

roflumilast
$14.9826per EA
High Outlier

Strength

250 ug/1

NDC

00310008839

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

1/1/2026

Active Ingredients

ROFLUMILAST

Approval Type

New Drug (NDA)

FDA Application

NDA022522

On Market Since

7/1/2015

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+2.8%

1Y

+3.1%

3Y

+8.9%

5Y

+18.5%

All

+33.6%

Generic Alternatives

1 alternative • Same active ingredient

DALIRESP 250 MCG TABLET
Brand
00310008828•AstraZeneca Pharmaceuticals LP
$14.9826

Related Drugs

Same classification

EUCRISA 2% OINTMENT
Brand
55724021111•Pfizer Inc.
$10.6810
per GM
EUCRISA 2% OINTMENT
Brand
55724021121•Pfizer Inc.
$12.6464
per GM
OTEZLA 20 MG TABLET
Brand
55513049760•Amgen Inc.
$89.9522
per EA
OTEZLA 30 MG TABLET
Brand
55513013760•Amgen Inc.
$90.6993
per EA